viloxazine · Qelbree

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Attention Deficit Hyperactivity Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Attention Deficit Hyperactivity Disorder
NCT07678827 · Alvogen Korea
2026-07 – 2027-09 · Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD
What this study did
NCT02736656 · Supernus Pharmaceuticals, Inc.
2016-02-02 – 2026-12 · Attention-Deficit/Hyperactivity Disorder
What this study did
NCT04143217 · Supernus Pharmaceuticals, Inc.
2020-01-23 – 2022-12-14 · Attention-Deficit/Hyperactivity Disorder
What this study did
NCT04016792 · Supernus Pharmaceuticals, Inc.
2019-08 – 2020-11 · ADHD
What this study did
NCT03247556 · Supernus Pharmaceuticals, Inc.
2017-11-20 – 2019-02-14 · ADHD
What this study did
Phase 2 (1)
Attention Deficit Hyperactivity Disorder
NCT02633527 · Supernus Pharmaceuticals, Inc.
2016-02-01 – 2016-07-25 · Attention-Deficit/Hyperactivity Disorder (ADHD)
What this study did
Phase 1/2 (1)
Attention Deficit Hyperactivity Disorder
NCT01107496 · Supernus Pharmaceuticals, Inc.
2010-06 – 2010-12 · Attention-Deficit/Hyperactivity Disorder (ADHD)
What this study did
Phase 4 (4)
Attention Deficit Hyperactivity Disorder
NCT04781140 · Supernus Pharmaceuticals, Inc.
2024-03-19 – 2028-01 · Attention-Deficit/Hyperactivity Disorder
What this study did
NCT06185985 · Supernus Pharmaceuticals, Inc.
2024-03-25 – 2024-12-11 · Attention-Deficit/Hyperactivity Disorder
What this study did
NCT04786990 · Supernus Pharmaceuticals, Inc.
2021-07-27 – 2023-07-26 · Attention-Deficit/Hyperactivity Disorder (ADHD)
What this study did
Other / comorbidity
NCT06259331 · Supernus Pharmaceuticals, Inc.
2023-05-23 – 2023-09-20 · Healthy Lactating Women
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Attention Deficit Hyperactivity Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Viloxazine (Qelbree): this drugApprovedSmall moleculenorepinephrine transporterReliable signal
NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91)
NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52)
Centanafadine (Simtriyo)ApprovedSmall moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint
Esreboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
not yet graded(overall)
No reviewed efficacy summary in this indication
Reboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)not yet gradedNo reviewed efficacy summary in this indication
Ampreloxetine (TD-9855)
Discontinued
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Qelbree (viloxazine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Attention Deficit Hyperactivity DisorderActive not recruiting
Est. primary completion 2026-12 · NCT02736656 · CT.gov ↗
What to watch
2027 (1)
September 2027 (1)
Phase 3Attention Deficit Hyperactivity DisorderNot yet recruiting
Est. primary completion 2027-09 · NCT07678827 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 4Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2028-01 · NCT04781140 · CT.gov ↗
What to watch

See the full readout calendar ↗